AI assistant
SYNTARA LIMITED — Call Transcript 2020
Nov 1, 2020
65830_rns_2020-11-01_2bb4ecae-e49b-4b9f-98cb-fbd886cf5354.pdf
Call Transcript
Open in viewerOpens in your device viewer
Media Release
2 November 2020
==> picture [154 x 45] intentionally omitted <==
PHARMAXIS TO HOST INVESTOR TELECONFERENCE
Pharmaxis Ltd will host a conference call to discuss today’s announcements concerning the US Food and Drug Administration’s decision on Bronchitol® for cystic fibrosis and the Company’s clinical program for myelofibrosis. We welcome participation from interested parties.
To access the call pre‐register (preferred option) or dial‐in direct (delays possible):
Investor Teleconference Monday 2 November, 11:00am (AEDT) Led by CEO Gary Phillips Conference ID: 10010656
1. Pre‐registration
‐ Participants can pre‐register by navigating to: https://s1.c conf.com/diamondpass/10010656‐B1sh00.html
Registered participants will receive their dial in number upon registration to enter the call automatically on the day.
2. Dial‐in directly (toll free)
| Conference ID:10010656 | Conference ID:10010656 | Conference ID:10010656 | Conference ID:10010656 |
|---|---|---|---|
| 1. Pre‐registrationParticipants can pre‐register by navigating to: https://s1.c‐conf.com/diamondpass/10010656‐B1sh00.htmlRegistered participants will receive their dial in number upon registration to enter the callautomaticallyon the day. | |||
| 2. Dial‐in directly (toll free) | |||
| Australia: | 1800 455 963 | Japan: | 0066 3386 8000 |
| Sydney: | 02 9007 8048 | Malaysia: | 1800 816 441 |
| New Zealand: | 0800 452 795 | Singapore: | 800 101 2702 |
| China: | 10800 140 1776 | South Africa: | 0800 984 013 |
| France: | 0800 913 734 | Spain: | 900 823 322 |
| Germany: | 0800 183 0918 | Switzerland: | 0800 802 498 |
| HongKong: | 800 968 273 | Taiwan: | 0080 112 7377 |
| India: | 0008 0010 08070 | UAE: | 8000 3570 2706 |
| Indonesia: | 007 803 321 8057 | UK: | 0800 051 1453 |
| Ireland: | 1800 948 607 | USA/Canada | 1 855 624 0077 |
| Other International(metered): +61 7 3145 4005 |
#ENDS#
SOURCE: Pharmaxis Ltd, Sydney, Australia
AUTHORISED FOR RELEASE TO ASX BY:
David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E [email protected]
Page 1 of 2
CONTACT:
Media: Felicity Moffatt: T +61 418 677 701, E [email protected] Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E [email protected]
Join the Pharmaxis mailing list or follow us:
==> picture [20 x 20] intentionally omitted <==
==> picture [20 x 20] intentionally omitted <==
About Pharmaxis
Pharmaxis Ltd is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.
Pharmaxis is developing its drug PXS‐5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS‐5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that is scheduled to begin recruitment in Q1 2021. PXS‐5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer.
Other drug candidates being developed from Pharmaxis’ amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and inflammatory diseases such as Duchenne Muscular Dystrophy.
Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.
Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au
Forward‐Looking Statements
Forward‐looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward‐looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward‐looking statements. These forward‐looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward‐looking statements as a result of new information, future events or otherwise.
Page 2 of 2